BioMelbourne Network
Progressing BioIndustry
News and Opinions
2013
May
SYNkinase Licensing a Pan-Kinase Binding Agent from Garvan and Cancer Therapeutics CRC Pty Ltd
17th May, 2013
SYNkinase Pty Ltd has signed a licence agreement with the Garvan Insitute ofMedical Research and Cancer Therapeutics CRC Pty Ltd to develop and market aunique Pan-Kinase Binding Agent to help screen human cells and tissues andidentify potential drug targets in diseased states.
The novel agent has the unique ability to detect most protein kinases critical cellsignalling proteins... read more…
5 Years of Women in Biotech Sharing Lunch
16th May 2013 Anita Petris, Program Manager BioMelbourne Network.
Many a project is conceived or deal signed over a cup of coffee or a glass of wine. So it was with the inception of the BioMelbourne Network’s ‘Connecting Women in Biotechnology Luncheon’ five years ago. It was from these humble beginnings that years later up to 400 women from the life sciences sector gather once a year to celeb... read more…
POLITICAL ALERT - CRCs The Perfect Partners For Innovation and Research
16th May, 2013Two Cooperative Research Centres (CRCs) have been awarded for the strength of their collaborative work in the fields of environmental contamination remediation and composite materials technology.
The CRC for Contamination Assessment and Remediation of the Environment (CRC CARE) and the CRC for Advanced Composite Structures (CRC-ACS) have been awarded 2013 CRC Star Awards.
Presen... read more…
April
Bionomics Presents Update on BNC101 at Leading US Antibody Conference
April 29 2013. Bionomics Limited (ASX: BNO) (ADR: BMICY) today announced that Dr Christopher Reyes, its Vice President of Research and Development Biologics, will provide an update on the BNC101 LGR5 cancer program and it’s CSC Rx Discovery™ platform at the 2013 PEGS “Promising New Targets – Oncology Stream” meeting in Boston, MA, USA.BNC101 entered Bionomics’ pipeline as a result of Bionomics... read more…
New ‘Superbug’ Antibiotic Approved for use in Australia
April 26 2013. An effective new antibiotic designed to specifically treat the common superbug* infection Clostridium difficile-associated diarrhoea will be available to patients in Australia from 14th May 2013.Melbourne biopharmaceutical company Specialised Therapeutics Australia Pty Ltd (STA) has received Therapeutic Goods Administration (TGA) approval to market the drug DIFICID (fidaxomicin)... read more…
2013 Melbourne Osaka Future Leaders Exchange Program
April 23 2013. This year marks the 35th Anniversary of Melbourne’s first sister city relationship with the City of Osaka.To mark this significant milestone The Rotary Club of Melbourne in conjunction with the City of Melbourne invites Melbourne professionals engaged in the biotech, pharma or life sciences sectors to apply to be part of a unique 10 day professional development program.The Melbo... read more…
Manufacture of BNC101 commences at Lonza
April 23 2013. Bionomics Limited (ASX: BNO) (ADR: BMICY) announced today that it has initiated manufacturing activities for BNC101, its lead anti-cancer stem cell candidate following completion of key preclinical studies. Dr Deborah Rathjen, Bionomics CEO & Managing Director commented, "The start of manufacturing activities for BNC101 signals a significant step towards clinical trials. We ant... read more…
Phosphagenics’ Partner Themis Completes Supply Agreement with Novartis for TPM/Diclofenac Gel
April 16 2013. Australian drug delivery technology company Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) today announced that its commercial partner, Themis Medicare Limited, made the following release to the Bombay Stock Exchange (BSE) post market on Friday 12 April. The release relates to the manufacture and supply of their specially formulated TPM/diclofenac gel to Novartis India Limited."... read more…
LBT enters in to exclusive discussions with European company for global commercialisation of diagnostic technology
April 15 2013. Medical technology company LBT Innovations Limited (ASX: LBT) has signed an agreement with the Switzerland-based laboratory instrumentation company, Hettich AG Switzerland, to finalise a partnership to complete the development and commercialisation of LBT’s Automated Plate Assessment System (APAS®).The agreement allows for exclusivity for one month while the two parties complete... read more…
Alchemia SPP Closes Heavily Oversubscribed
April 12 2013. Australian drug discovery and development company Alchemia Limited (ASX: ACL) (“Alchemia” or the “Company”) has successfully closed its share purchase plan (“SPP”) heavily oversubscribed.After scaling back demand, the Company has raised $2.75 million. This capital is in addition to the $10.2 million recently raised via an institutional placement. Following a scale back and round... read more…
